Last reviewed · How we verify
NeuroVax
At a glance
| Generic name | NeuroVax |
|---|---|
| Also known as | IR902 TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1 |
| Sponsor | Immune Response BioPharma, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis (PHASE1)
- A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis (PHASE2, PHASE3)
- A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeuroVax CI brief — competitive landscape report
- NeuroVax updates RSS · CI watch RSS
- Immune Response BioPharma, Inc. portfolio CI